NeoGenomics, Inc. (FRA:NG9)
Germany · Delayed Price · Currency is EUR | Market Cap | 810.15M -28.0% |
| Revenue (ttm) | 619.47M +10.1% |
| Net Income | -92.00M |
| EPS | -0.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 45.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 27 |
| Open | 6.70 |
| Previous Close | 6.65 |
| Day's Range | 6.20 - 6.70 |
| 52-Week Range | 4.20 - 11.30 |
| Beta | n/a |
| RSI | 22.02 |
| Earnings Date | Apr 29, 2026 |
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer.
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.
NeoGenomics to Present New ctDNA Research at SABCS 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.
NeoGenomics Reports Third Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, Oct. 28, 2025.
NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026
NeoGenomics NEO is in Phase 18, the final stage of its Adhishthana Cycle on the weekly charts. After more than 850 days of consolidation, the stock shows little sign of breaking out.
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. NTRA asserted against NeoGenomics, Inc.'s NEO v1.1 ...
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
FORT MYERS, Fla.--(BUSINESS WIRE)--Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera.
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
NeoGenomics Reports Second Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2025.
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will debut its PanTracer Family and unveil the Paletrra platform at ASCO 2025, advancing precision oncology diagnostics.